The 20 Best Bladder Cancer Doctors Near Me

Dr. Sima Porten is a specialist in cancers of the genital and urinary organs. She is a member of the urologic oncology team at the UCSF Helen Diller Family Comprehensive Cancer Center. Her clinical interests include the diagnosis and treatment of genitourinary cancer, particularly bladder cancer, upper tract urothelial cancer, kidney cancer and high-risk prostate cancer. Porten's research focuses mainly on the diagnosis and management of urothelial carcinoma, a cancer involving parts of the kidney, bladder and ureter (the tube connecting each kidney to the bladder). In studying the biologic or genetic basis of urothelial carcinoma, she hopes to develop new tests and treatments to bring personalized medicine to patients with bladder cancer. Porten received her undergraduate, medical and master of public health degrees from Northwestern University. During medical school, she was inducted into the Alpha Omega Alpha Honor Medical Society and also completed a fellowship through the Howard Hughes Medical Institute–National Institutes of Health Research Scholars Program. She then completed her urology residency training at UCSF, where she received the Julius R. Krevans Award for Clinical Excellence. During her training in urologic oncology at the University of Texas MD Anderson Cancer Center, she was awarded a John Quale Travel Fellowship for her research in bladder cancer. Porten is an active member of the American Urological Association, American Society of Clinical Oncology, Society of Women in Urology and Society of Urologic Oncology. Dr. Porten is rated as an Elite provider by MediFind in the treatment of Bladder Cancer. She is also highly rated in 11 other conditions, according to our data. Her clinical expertise encompasses Bladder Cancer, Urothelial Cancer, Muscle Invasive Bladder Cancer, Nephrectomy, and Reconstructive Urology Surgery. Dr. Porten is board certified in American Board Of Urology, Urology. Dr. Porten is currently accepting new patients.

Sumanta Pal is an Oncologist practicing medicine in Duarte, California. Dr. Pal is rated as an Elite provider by MediFind in the treatment of Bladder Cancer. He is also highly rated in 25 other conditions, according to our data. His clinical expertise encompasses Renal Cell Carcinoma (RCC), Urothelial Cancer, Bladder Cancer, Nephrectomy, and Lymphadenectomy.

Alexander Kutikov is a Urologist practicing medicine in Rockledge, Pennsylvania. Dr. Kutikov is rated as an Elite provider by MediFind in the treatment of Bladder Cancer. He is also highly rated in 26 other conditions, according to our data. His clinical expertise encompasses Renal Cell Carcinoma (RCC), Muscle Invasive Bladder Cancer, Bladder Cancer, Nephrectomy, and Cystectomy. Dr. Kutikov is board certified in American Board Of Urology.

Ashish Kamat is a Urologist practicing medicine in Cary, North Carolina. Dr. Kamat is rated as an Elite provider by MediFind in the treatment of Bladder Cancer. He is also highly rated in 15 other conditions, according to our data. His clinical expertise encompasses Bladder Cancer, Non-Muscle Invasive Bladder Cancer, Muscle Invasive Bladder Cancer, Cystectomy, and Lymphadenectomy.

Guido Dalbagni is a Urologist practicing medicine in New York, New York. Dr. Dalbagni is rated as an Elite provider by MediFind in the treatment of Bladder Cancer. He is also highly rated in 21 other conditions, according to our data. His clinical expertise encompasses Bladder Cancer, Urothelial Cancer, Upper Tract Urothelial Carcinoma (UTUC), Cystectomy, and Nephrectomy. Dr. Dalbagni is currently accepting new patients.

Tanya Dorff is an Oncologist practicing medicine in Duarte, California. Dr. Dorff is rated as an Elite provider by MediFind in the treatment of Bladder Cancer. She is also highly rated in 22 other conditions, according to our data. Her clinical expertise encompasses Prostate Cancer, Penile Cancer, Familial Prostate Cancer, Prostatectomy, and Orchiectomy.

Daniel Geynisman is an Oncologist practicing medicine in Philadelphia, Pennsylvania. Dr. Geynisman is rated as an Elite provider by MediFind in the treatment of Bladder Cancer. He is also highly rated in 18 other conditions, according to our data. His clinical expertise encompasses Renal Cell Carcinoma (RCC), Muscle Invasive Bladder Cancer, Bladder Cancer, Nephrectomy, and Orchiectomy. Dr. Geynisman is board certified in American Board Of Internal Medicine - Medical Oncology.

Elizabeth Plimack is an Oncologist practicing medicine in Philadelphia, Pennsylvania. Dr. Plimack is rated as an Elite provider by MediFind in the treatment of Bladder Cancer. She is also highly rated in 15 other conditions, according to our data. Her clinical expertise encompasses Renal Cell Carcinoma (RCC), Muscle Invasive Bladder Cancer, Bladder Cancer, Nephrectomy, and Orchiectomy. Dr. Plimack is board certified in American Board Of Internal Medicine - Medical Oncology.

Marianna Koczywas is an Oncologist practicing medicine in Duarte, California. Dr. Koczywas is rated as an Elite provider by MediFind in the treatment of Bladder Cancer. She is also highly rated in 26 other conditions, according to our data. Her clinical expertise encompasses Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Mesothelioma, EGFR Positive Lung Cancer, and Tissue Biopsy.

Gary Steinberg is a Urologist practicing medicine in Chicago, Illinois. Dr. Steinberg is rated as an Elite provider by MediFind in the treatment of Bladder Cancer. He is also highly rated in 17 other conditions, according to our data. His clinical expertise encompasses Bladder Cancer, Non-Muscle Invasive Bladder Cancer, Muscle Invasive Bladder Cancer, Cystectomy, and Ureteral Reconstruction. Dr. Steinberg is currently accepting new patients.

Dr. Tolaney is Chief of the Division of Breast Oncology at Dana-Farber Cancer Institute, and Associate Professor of Medicine at Harvard Medical School.  She is a breast medical oncologist whose research focuses on the development of novel therapies in the treatment of breast cancer.  She has been instrumental in developing several treatment approaches for breast cancer, including approaches focused on tailoring therapy for early stage HER2+ disease, use of cdk 4/6 inhibitors, antibody drug conjugates, and immunotherapy.She is a member of the National Cancer Institute Breast Cancer Steering Committee and is Vice Chair for Late-Stage Development in Breast Cancer in the Alliance for Clinical Trials in Oncology. Her research has been funded by the Breast Cancer Research Foundation and Susan G. Komen. She currently chairs multiple phase 3 trials in breast cancer and serves on several steering committees for practice-changing trials.  Her work has been published in journals such as the New England Journal of Medicine, Lancet, Lancet Oncology, Journal of Clinical Oncology, and others. She received her undergraduate degree from Princeton University in 1998 and her medical degree from UC San Francisco in 2002. She subsequently completed her residency in Internal Medicine at Johns Hopkins University, and fellowships in hematology and medical oncology at Dana-Farber Cancer Institute. She obtained a Masters in Public Health from the Harvard School of Public Health in 2007. In 2008, she joined the staff of Dana-Farber Cancer Institute and Brigham and Women's Hospital. Dr. Tolaney is rated as an Elite provider by MediFind in the treatment of Bladder Cancer. She is also highly rated in 15 other conditions, according to our data. Her clinical expertise encompasses Breast Cancer, HER-2 Positive Breast Cancer, Inflammatory Breast Cancer, and Triple-Negative Breast Cancer. Dr. Tolaney is board certified in Medical Oncology. Dr. Tolaney is currently accepting new patients.

Nirmish Singla is an Oncologist practicing medicine in Baltimore, Maryland. Dr. Singla is rated as an Elite provider by MediFind in the treatment of Bladder Cancer. He is also highly rated in 22 other conditions, according to our data. His clinical expertise encompasses Upper Tract Urothelial Carcinoma (UTUC), Renal Cell Carcinoma (RCC), Urothelial Cancer, Nephrectomy, and Orchiectomy. Dr. Singla is board certified in American Board Of Urology. Dr. Singla is currently accepting new patients.

Dr. Noah Hahn is a medical oncologist in the Baltimore area, caring for patients with bladder cancer. He serves as the deputy director of the Greenberg Bladder Cancer Institute at the Johns Hopkins School of Medicine. Dr. Hahn earned his M.D. from Indiana University School of Medicine. He completed his residency in internal medicine at Duke University School of Medicine and performed a fellowship in medical oncology at Indiana University School of Medicine. Dr. Hahn joined the Johns Hopkins faculty in 2014. Prior to joining Johns Hopkins, Dr. Hahn was the director of the Genitourinary Medical Oncology Program at Indiana University and chief scientific officer for the Hoosier Oncology Group, a cancer research organization that evaluates innovative and promising approaches to cancer treatment. He is currently conducting clinical trials to test new therapies for bladder cancer, including those for early stage bladder cancer. Dr. Hahn is a member of the Bladder Cancer Task Force for the National Cancer Institute’s Genitourinary Cancer Steering Committee and is chair of the Bladder Cancer Subcommittee of the Eastern Cooperative Oncology Group. Dr. Hahn is rated as an Elite provider by MediFind in the treatment of Bladder Cancer. He is also highly rated in 15 other conditions, according to our data. His clinical expertise encompasses Bladder Cancer, Urothelial Cancer, Muscle Invasive Bladder Cancer, Upper Tract Urothelial Carcinoma (UTUC), and Nephrectomy. Dr. Hahn is currently accepting new patients.

I enjoy traveling, dancing and food. Dr. Shroff is rated as an Elite provider by MediFind in the treatment of Bladder Cancer. She is also highly rated in 11 other conditions, according to our data. Her clinical expertise encompasses Cholangiocarcinoma (Bile Duct Cancer), Pancreatic Cancer, Gallbladder Cancer, Pancreaticoduodenectomy, and Pancreatectomy. Dr. Shroff is board certified in American Board Of Internal Medicine/Medical Oncology. Dr. Shroff is currently accepting new patients.

Dr. Mark A. Preston is a urologic surgeon at Brigham and Women’s Hospital and Associate Professor of Surgery at Harvard Medical School. Dr. Preston received his Medical Degree from the University of Ottawa in Canada, where he also completed his residency training in Urology. He completed a three-year accredited fellowship in Urologic Oncology at Massachusetts General Hospital including a Masters of Public Health from the Harvard School of Public Health with a concentration in clinical effectiveness. He is board certified in Urology.Dr. Preston’s clinical interests include urologic oncology (bladder, kidney, prostate and testicular cancer) and minimally invasive surgery. Dr. Preston’s research focuses on the epidemiology of prostate and kidney cancer risk with an emphasis on predictive biomarkers and pharmacoepidemiology. Dr. Preston is rated as an Elite provider by MediFind in the treatment of Bladder Cancer. He is also highly rated in 19 other conditions, according to our data. His clinical expertise encompasses Bladder Cancer, Muscle Invasive Bladder Cancer, Prostate Cancer, Cystectomy, and Prostatectomy. Dr. Preston is board certified in Urology. Dr. Preston is currently accepting new patients.

Seth P. Lerner, MD, is Professor of Urology and holds the Beth and Dave Swalm Chair in Urologic Oncology, in the Scott Department of Urology, Baylor College of Medicine. He is Director of Urologic Oncology and the Multidisciplinary Bladder Cancer Program and Faculty Group Practice Medical Director for the Urology Clinic. He earned his medical degree from Baylor College of Medicine, completed a surgical internship at Virginia Mason Hospital in Seattle, and returned to Baylor for his residency training. He completed a two-year fellowship at the University of Southern California in urologic oncology and reconstructive surgery under Peter Jones and Don Skinner before returning to join the full-time Baylor faculty in 1992. His clinical practice, education, and research activities are devoted to urologic oncology and particularly lower and upper tract urothelial cancer. Dr. Lerner is author of more than 160 peer-reviewed articles, and co-editor of a comprehensive Textbook of Bladder Cancer. Dr. Lerner is an active member of the prestigious American Association of Genitourinary surgeons and is listed routinely among America's Top Doctors and Best Doctors in America. He established and directs the multi-disciplinary Bladder Cancer Research Program at Baylor, and his research interests include use of selective estrogen receptor modulators for treatment of bladder cancer, gene therapy, targeted molecular therapeutics, and outcomes of radical cystectomy and pelvic lymphadenectomy. He has 22 years of experience as a clinical investigator for both NCI and industry funded clinical trials. He is the PI of the ongoing SWOG NCI Phase III trial comparing extended vs. standard pelvic lymphadenectomy at time of radical cystectomy for muscle invasive bladder cancer. He is active in the leadership of several national bladder cancer research enterprises including chair of the Local Bladder Cancer committee of SWOG, co-chair of the NCI's Bladder Cancer Task Force and the Analysis Working Group of The Cancer Genome Atlas Project for muscle invasive bladder cancer. He is very active in the Bladder Cancer Advocacy Network (BCAN) as a member of the Board of Directors, past chair of the Bladder Cancer Think Tank and co-chair of the management committee of the Bladder Cancer Research Network. Dr. Lerner is rated as an Elite provider by MediFind in the treatment of Bladder Cancer. He is also highly rated in 11 other conditions, according to our data. His clinical expertise encompasses Bladder Cancer, Urothelial Cancer, Muscle Invasive Bladder Cancer, Cystectomy, and Lymphadenectomy. Dr. Lerner is currently accepting new patients.

Dr. Max Kates is the R. Christian B. Evensen Professor and an associate professor of urology and oncology at the Brady Urological Institute at Johns Hopkins. He also directs the Division of Urologic Oncology for the Brady Urological Institute. Dr. Kates completed his undergraduate degree at Wesleyan University in Connecticut before pursuing his medical degree at Mount Sinai School of Medicine in New York. He then went on to train at Johns Hopkins for his urologic residency and Society of Urologic Oncology (SUO) fellowship. Dr. Kates has expertise in all areas of urologic oncology, with a particular emphasis on bladder and prostate cancer. With training in open, endoscopic, and robotic surgical approaches, Dr. Kates’ surgical philosophy is to assess the unique needs of each patient, and develop the right treatment plan for their malignancy. He is very hands on in his approach in the clinic and the operating room, and believes open communication with the patient, the patient’s family, and referring providers is key to ensuring a speedy recovery. As the clinical director of the bladder cancer multidisciplinary clinic, Dr. Kates works with the team at the Johns Hopkins Greenberg Bladder Cancer Institute to deliver a personalized approach to bladder cancer utilizing cutting edge precision medicine approaches. Dr. Kates’ research interests involve novel treatments for cancers of the urinary tract. Dr. Kates has authored more than 135 journal articles in the fields of bladder, prostate, and kidney cancer. He currently has a provisional patent for a novel intravesical chemotherapy developed with nano-engineer collaborators. Additionally, Dr. Kates has made important discoveries into the mechanism of action of intravesical BCG, the most common treatment for bladder cancer. He is the principal investigator on multiple trials, and is currently leading EA8212 BRIDGE, which is a randomized trial open in over 150 centers in the United States comparing BCG to GemDoce chemotherapy for early stage bladder cancer. To inquire about an appointment or make a referral, Dr. Kates can be contacted by phone (410) 614-0009. Dr. Kates is rated as an Elite provider by MediFind in the treatment of Bladder Cancer. He is also highly rated in 14 other conditions, according to our data. His clinical expertise encompasses Bladder Cancer, Urothelial Cancer, Muscle Invasive Bladder Cancer, Cystectomy, and Nephrectomy. Dr. Kates is board certified in American Board Of Urology. Dr. Kates is currently accepting new patients.

Dr. Mossanen is a graduate of the University of California, Los Angeles (UCLA) in Los Angeles, CA and received his medical degree from the David Geffen School of Medicine at UCLA. He also holds a Master of Public Health from the Harvard T.H. Chan School of Public Health in Boston, MA. Dr. Mossanen completed a residency in Urology from the University of Washington in Seattle, WA followed by a fellowship in Urologic Oncology in the Combined Harvard Urologic Oncology Fellowship at Massachusetts General Hospital and Brigham and Women’s Hospital. Dr. Mossanen has been board certified by the American Board of Urology since 2020.His research and clinical interests include: bladder cancer, kidney cancer, kidney masses/cysts, laparoscopic surgery, penile cancer, prostate cancer, robotic surgery, testicular cancer. Dr. Mossanen is rated as an Elite provider by MediFind in the treatment of Bladder Cancer. He is also highly rated in 18 other conditions, according to our data. His clinical expertise encompasses Bladder Cancer, Muscle Invasive Bladder Cancer, Non-Muscle Invasive Bladder Cancer, Cystectomy, and Nephrectomy. Dr. Mossanen is board certified in Urology. Dr. Mossanen is currently accepting new patients.

David Mcdermott is an Oncologist practicing medicine in Boston, Massachusetts. Dr. Mcdermott is rated as an Elite provider by MediFind in the treatment of Bladder Cancer. He is also highly rated in 15 other conditions, according to our data. His clinical expertise encompasses Renal Cell Carcinoma (RCC), Melanoma, Chromophobe Renal Cell Carcinoma, WT1-Related Wilms Tumor Syndromes, and Nephrectomy. Dr. Mcdermott is board certified in American Board Of Internal Medicine. Dr. Mcdermott is currently accepting new patients.

Dr. Jean Hoffman-Censits is a genitourinary cancer specialist in Baltimore, caring for patients with urothelial cancers of the bladder and upper tract. She serves as co-leader of the Women’s Bladder Cancer Program in the Greenberg Bladder Cancer Institute at the Johns Hopkins University School of Medicine. Dr. Hoffman-Censits received her undergraduate degree in neuroscience from Trinity College. She earned her M.D. degree from the Sidney Kimmel Medical College of Thomas Jefferson University. She completed her residency at Thomas Jefferson University Hospital and performed a fellowship in hematology and oncology at Temple University Medical Center. She joined the Johns Hopkins faculty in 2018. Dr. Hoffman-Censits's research interests focus on urothelial cancers. Her clinical research has helped identify urothelial cancer sub-types and establish new treatments for bladder and upper tract urothelial cancers. She is a member of the American Medical Association, the American Society of Clinical Oncology, the American Urological Association and the Society for Immunotherapy of Cancer. Dr. Hoffman-Censits is rated as an Elite provider by MediFind in the treatment of Bladder Cancer. She is also highly rated in 12 other conditions, according to our data. Her clinical expertise encompasses Urothelial Cancer, Bladder Cancer, Muscle Invasive Bladder Cancer, Nephrectomy, and Bladder Reconstruction. Dr. Hoffman-Censits is board certified in American Board Of Internal Medicine. Dr. Hoffman-Censits is currently accepting new patients.